Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 514 participants.

Also called NCT02787551

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 514 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02787551
Other papers using this trial's data
  • Fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß-cell function in people with type 2 diabetes Diabetes, obesity & metabolism, 2022-06 DOI, PubMed 35257461, PMC9314929 In the PMC Open Access subset under CC BY-NC.
  • Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial Diabetes care, 2019-11 DOI, PubMed 31530665

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Estonia, Germany, Israel, Italy, Romania, Slovakia, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02787551. Randomized; no masking; primary purpose treatment. Start 2016-07-06 (actual); primary completion 2018-05-25 (actual). Results posted on 2019-06-12.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
Acronym
LixiLan-G
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Insulin glargine/lixisenatide fixed ratio combination
Intervention (Drug)
liraglutide
Intervention (Drug)
exenatide
Intervention (Drug)
exenatide extended-release
Intervention (Drug)
albiglutide
Intervention (Drug)
dulaglutide
Intervention (Drug)
Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct02787551
Content hash
c67b6c8b066b2b04547fc87b66535906f8481281385dcdf9e990356a922e70f7